A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male Subjects

Erectile Dysfunction Clinical Trial

Official title:

A Randomized, Blind, Placebo-controlled, Three-way Crossover Study Evaluating the Interaction of TPN171H Tablets and Alcohol in Healthy Chinese Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05316428
• Other study ID #: TPN171H-08
• Status: Completed
• Phase: Phase 1
• Start date: February 24, 2022
• Est. completion date: April 6, 2022

Study information

• Verified date: February 2022
• Source: Vigonvita Life Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is primarily to evaluate the effects of taking TPN171H tablets with alcohol on blood pressure, pulse,and pharmacokinetic in Chinese healthy male subjects.

Description:

This study will be divided into two parts: pre-test and formal test. The pre-trial is an open design to evaluate the safety and tolerability of TPN171H tablets in combination with alcohol in healthy male subjects. Two subjects at 5 mg and 10 mg doses will be taken with alcohol, blood pressure (SBP and DBP), pulse, alcohol breath monitoring and PK blood sample collection were required, and the time point was the same as the formal test.

The dosage of TPN171H tablets in the formal trial will be determined according to the preliminary test results.

The formal trial is a single-centre, blind, randomized, placebo-controlled, three-period, three-way crossover study, in which each subject will be randomized to receive each of the following three treatments with a washout period of at least 3 days between treatments:

Treatment A: a single oral dose of one10 mg or 5 mg TPN171H tablet plus an oral dose of alcohol drink mixed with fruit juice (0.5 g of absolute ethanol per kilogram of body weight).

Treatment B: a single oral dose of one placebo tablet plus an oral dose of alcohol drink mixed with fruit juice (0.5 g of absolute ethanol per kilogram of body weight).

Treatment C: a single oral dose of one10 mg or 5 mg TPN171H tablet plus an oral dose of placebo drink mixed with fruit juice.

For each treatment period, supine blood pressure and pulse rate will be measured pre-dose and every 15 minutes for 4 hours post-dose,and at 6h,8h,24h and 48h post-dose. Alcohol levels using a breathalyzer will be measured at pre-dose and up to 8 hours post dose during all 3 treatments by designated unblinded personnel.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: April 6, 2022
• Est. primary completion date: April 2, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 21 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Voluntarily sign and abide by the contents of the informed consent;

2. Adult male subjects, either 21 to 45 years of age,

3. Body weight =55 kg; Body mass index (BMI) in the range of 19.0-26.0 kg/m2 (including the critical value);

4. Subjects must agree to use at least one method of birth control for at least three months from the time of the first dose to at least the last;

5. Normal or abnormal important indicators of physical examination, vital signs examination, electrocardiogram examination and laboratory examination have no clinical significance as judged by the researcher.

Exclusion Criteria:

1. Unable to consume alcohol according to 0.5 g/kg (body weight);

2. After ingestion of 0.5 g/kg alcohol, the instrument showed alcohol concentration =120 mg/100 mL after exhalation, or moderate or severe acute alcoholism, which was judged by the investigator to be unfit to continue to participate in the study (see Appendix 1 for clinical classification of acute alcoholism);

3. Systolic pressure in decubitus (semi-decubitus) position < 90 or =140 mmHg; Diastolic pressure in decubitus (semi-decubitus) position < 60 or =90 mmHg;

4. Known allergic history, patients with allergic diseases or allergic predisposition to the study product or any of its components or related product;

5. May significantly affect drug absorption, distribution, metabolism and excretion of any surgical situation or condition, or may pose a hazard to participate in research subjects of any surgical situation or condition, such as the history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), gastroenteritis, gastrointestinal ulcers, gastrointestinal bleeding history etc. (except for gallbladder removal);

6. Patients with myocardial infarction, severe/unstable angina pectoris, coronary artery/peripheral artery bypass graft, congestive heart failure, severe arrhythmias, and cerebrovascular accidents, including transient ischemic attack, within 6 months prior to the administration of the study drug;

7. Those who had used any drugs to inhibit or induce drug metabolism in the liver within 4 weeks before enrollment or needed to use any drugs in combination during the study period; Patients taking nitrates in any form;

8. Known history of the following eye diseases: non-avascular ischemic optic neuropathy (NAION), abnormal color vision, hereditary retinal degeneration (e.g. Retinitis pigmentosa), macular degeneration;

9. Known history of sudden hearing loss or loss;

10. A history of postural hypotension;

11. Patients with blood loss >400 mL within 3 months before inclusion;

12. Participated in clinical research of other drugs or medical devices within 3 months prior to inclusion;

13. Current or previous alcoholics (drinking more than 14 standard units per week. 1 standard unit containing 14 g alcohol, such as 360 mL beer or 45 mL 40% spirits or 150 mL wine), or positive breath test for alcohol;

14. Have a history of drug use or have been screened positive for drug abuse;

15. Smokers who smoked more than 10 cigarettes a day within 6 months prior to inclusion;

16. Human immunodeficiency virus antibody (HIV), hepatitis C virus antibody (anti-HCV), hepatitis B surface antigen (HBsAg), treponema pallidum antibody (anti-TP) positive;

17. Alcohol sensitivity test positive;

18. There were other factors that the investigator considered inappropriate for the study.

Related Conditions & MeSH terms

• Alcohol
• Erectile Dysfunction
• Phosphodiesterase Inhibitor

Intervention

Drug:
• TPN171H tablet plus alcohol
10 mg TPN171H tablet QD plus 0.5 g/kg alcohol

Other:
• alcohol
0.5 g/kg alcohol

Drug:
• TPN171H tablet
10 mg TPN171H tablet QD

Locations

Country	Name	City	State
China	Shanghai Xuhui Central Hospital	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Vigonvita Life Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum change in blood pressure (SBP and DBP)	Maximum change in decubitus (semi-decubitus) blood pressure (SBP and DBP) from baseline	48 hours after treatment
Primary	Maximum change in pulse	Maximum change from baseline in decubitus (semi-decubitus) position;	48 hours after treatment
Primary	The area under effect-time curve (AUEC0- 4h) of supine systolic (SBP) and diastolic (DBP) blood pressure, and pulse	The area under effect-time curve (AUEC0- 4h) of supine systolic (SBP) and diastolic (DBP) blood pressure, and pulse relative to baseline change.	4 hours after treatment